keyword
MENU ▼
Read by QxMD icon Read
search

oral antineoplastic

keyword
https://www.readbyqxmd.com/read/29197167/to-take-or-not-to-take-with-meals-unraveling-issues-related-to-food-effects-labeling-for-oral-antineoplastic-drugs
#1
Jiexin Deng, Satjit S Brar, Lawrence J Lesko
There has been controversy regarding whether bioavailability of certain oral oncology drugs should be maximized by taking these medications with food, irrespective of label instructions in the dosing and administration section. To provide insight into this controversy, we conducted an in-depth analysis for oral antineoplastic drugs approved by the Food and Drug Administration in 2000-2016 and identified important issues influencing food labeling decisions. Furthermore, a case study involving sonidegib, a drug approved for locally advanced basal cell carcinoma with a significant food effect on exposure, was used to demonstrate the consequences of failure to adhere to food label recommendations using drug-specific population pharmacokinetic and exposure-toxicity models...
December 2, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/29176395/integrated-safety-summary-for-trifluridine-tipiracil-tas-102
#2
Alfredo Falcone, Atsushi Ohtsu, Eric Van Cutsem, Robert J Mayer, Michele Buscaglia, Johanna C Bendell, Scott Kopetz, Paul Bebeau, Takayuki Yoshino
Trifluridine/tipiracil, an oral treatment combining trifluridine (an antineoplastic thymidine-based nucleoside analog) and tipiracil hydrochloride (a thymidine phosphorylase inhibitor), led to significant improvement in overall survival in metastatic colorectal cancer (mCRC) patients refractory to standard therapy in the phase III RECOURSE trial. Here, we report an integrated summary of the safety of trifluridine/tipiracil. The main safety analysis includes integrated data from the RECOURSE and J003 studies (safety data group 2) of patients with refractory mCRC receiving trifluridine/tipiracil at the recommended starting dose: 35 mg/m twice daily for 5 days with 2 days' rest for 2 weeks, followed by a 14-day rest (one cycle)...
November 24, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29175466/photodynamic-therapy-for-treatment-of-oral-mucositis-pilot-study-with-pediatric-patients-undergoing-chemotherapy
#3
Vânia Cavalcanti Ribeiro da Silva, Fabiana Moura da Motta Silveira, Gabriela Souza Lima, Mônica Moreira Dias da Cruz, Arnaldo de França Caldas Júnior, Gustavo Pina Godoy
BACKGROUND: Oral mucositis has become a major factor dose-limiting toxicity of antineoplastic treatment. AIM: The aim of the present study was to evaluate the effect of photodynamic therapy (PDT) and low level laser therapy (LLLT) on the treatment of chemotherapy-induced mucositis in pediatric patients. METHODS: An open, controlled, and blind, randomized clinical trial was conducted with 29 patients, from 10 months to 18 years old, who were divided into two groups...
November 22, 2017: Photodiagnosis and Photodynamic Therapy
https://www.readbyqxmd.com/read/29138046/novel-cremochylomicrons-for-improved-oral-bioavailability-of-the-antineoplastic-phytomedicine-berberine-chloride-optimization-and-pharmacokinetics
#4
Manal A Elsheikh, Yosra S R Elnaggar, Dalia A Hamdy, Ossama Y Abdallah
Berberine chloride (BER) is an antineoplastic phytomedicine that combat non-Hodgkin lymphoma. BER suffers from low oral bioavailability due to p-glycoprotein efflux and first-pass metabolism. Lymphatic drug targeting recently gained a profound attention due to circumventing hepatic first-pass metabolism and targeting lymph diseases. Therefore, novel BER-loaded cremochylomicrons were elaborated to mitigate BER drawbacks and enhance its lymphatic targeting and bioavailability. Optimized cremochylomicron was prepared with 2...
November 11, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29119052/synergistic-anticancer-activity-of-a-novel-oral-chemotherapeutic-agent-containing-trifluridine-and-tipiracil-in-combination-with-anti-pd-1-blockade-in-microsatellite-stable-type-murine-colorectal-cancer-cells
#5
Norihiko Suzuki, Hiroshi Tsukihara, Fumio Nakagawa, Takashi Kobunai, Teiji Takechi
Trifluridine/tipiracil (FTD/TPI) is a combination of FTD, an antineoplastic thymidine-based nucleoside analog, and TPI, which acts to enhance the bioavailability of FTD in vivo. It is used to treat patients with unresectable advanced or recurrent colorectal cancer that is refractory to standard therapies. We investigated the anticancer activity of FTD/TPI combined with anti-mouse programed cell death 1 (PD-1) monoclonal antibody (mAb) against CMT-93 cells, which are microsatellite stable (MSS)-type murine colorectal cancer cells...
2017: American Journal of Cancer Research
https://www.readbyqxmd.com/read/29105806/the-orally-active-pterocarpanquinone-lqb-118-exhibits-cytotoxicity-in-prostate-cancer-cell-and-tumor-models-through-cellular-redox-stress
#6
Thiago Martino, Tarana A Kudrolli, Binod Kumar, Isis Salviano, André Mencalha, Marsen Garcia P Coelho, Graça Justo, Paulo R Ribeiro Costa, Kátia C Carvalho Sabino, Shawn E Lupold
BACKGROUND: The targeted induction of reactive oxygen species (ROS) is a developing mechanism for cancer therapy. LQB-118 is a pterocarpanquinone and ROS-inducing agent with proven antineoplastic activity. Here, LQB-118 efficacy and mechanism of activity, were examined in Prostate Cancer (PCa) cell and tumor models. METHODS: PC3, LNCaP, and LAPC4 PCa cells were applied. Dicoumarol treatment was used to inhibit quinone reductase activity. N-acetylcysteine (NAC) was applied as a ROS scavenger...
November 6, 2017: Prostate
https://www.readbyqxmd.com/read/29104720/dasatinib-induced-seborrheic-dermatitis-like-eruption
#7
Ryan R Riahi, Philip R Cohen
Dasatinib is an oral tyrosine kinase inhibitor approved for imatinib-resistant chronic myelogenous leukemia. It has been investigated in treating other neoplasms, including non-small-cell lung cancer and a subset of melanomas. Seborrheic dermatitis is characterized by erythematous patches or plaques with scaling typically affecting the external ear, glabella, hair-bearing areas of the face, nasolabial fold, and scalp. Antitumor agents are often associated with mucocutaneous side effects, including seborrheic dermatitis...
July 2017: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/29090585/the-importance-of-pharmaceutical-care-in-oncologic-patients-undergoing-oral-antineoplastic-treatment-a-pilot-study-on-adherence-quality-of-life-and-perceptions-of-the-information-received
#8
Graziele Baldan Ferrari, Marília Berlofa Visacri, Júlia Coelho França Quintanilha, Gabriela Galhardo de Vito, Cristina Rosa Barbosa, Lara Paro Dias, Carmen Silvia Passos Lima, Patricia Moriel
No abstract text is available yet for this article.
October 1, 2017: American Journal of Medical Quality: the Official Journal of the American College of Medical Quality
https://www.readbyqxmd.com/read/29016351/ameliorative-effect-of-gallic-acid-on-doxorubicin-induced-cardiac-dysfunction-in-rats
#9
Temiday O Omóbòwálé, Ademola A Oyagbemi, Ayorinde M Folasire, Temitayo O Ajibade, Ebunoluwa R Asenuga, Olumuyiwa A Adejumobi, Olufunke E Ola-Davies, Orotusin Oyetola, Gana James, Adeolu A Adedapo, Momoh A Yakubu
BACKGROUND: The use of doxorubicin (DOX) as an antineoplastic agent has been greatly limited because of the myriad of toxic sequelae associated with it. The aim of this study was to assess the protective effects of gallic acid (GA) on DOX-induced cardiac toxicity in rats. METHODS: Sixty male rats (Wistar strain) were used in this study. They were divided into six groups (A-F) each containing 10 animals. Group A was the control. Rats in Groups B, C, and D were treated with DOX at the dosage of 15 mg/kg body weight i...
October 9, 2017: Journal of Basic and Clinical Physiology and Pharmacology
https://www.readbyqxmd.com/read/28987366/the-impact-of-gallic-acid-on-the-methotrexate-induced-kidney-damage-in-rats
#10
Halil Asci, Ozlem Ozmen, Hamit Yasar Ellidag, Bunyamin Aydin, Ercan Bas, Necat Yilmaz
Prolonged use of an antineoplastic agent methotrexate (MTX), can cause numerous side effects such as nephrotoxicity. The aim of this study was to examine the effects of MTX on kidneys and demonstrate the protective effects of gallic acid (GA). Twenty-four, male, rats distributed into three groups. Each groups consisted eight rats and only saline was administered to the control group. The MTX group received a single dose (20 mg/kg) MTX intraperitoneally. The MTX + GA group received same dose MTX and 100 mg/kg GA orally during the 7 days...
October 2017: Journal of Food and Drug Analysis
https://www.readbyqxmd.com/read/28969534/perioperative-management-of-female-hormone-medications
#11
Lynsey A Seim, Joan M Irizarry-Alvarado
BACKGROUND: No clear guideline exists for the management of female hormone therapy in the perioperative period. Besides oral contraceptives (OCPs), hormone medications have been prescribed to treat cancer, osteoporosis, and menopausal symptoms. Since the introduction of OCPs in the 1960s, the thromboembolic risk associated with these medications has been studied and alterations have been made in the hormone content. The continuation of hormone therapy in the perioperative period and its possible interactions with commonly used anesthetic agents are important information for all perioperative health care providers...
September 26, 2017: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/28921641/pharmacokinetic-guided-dosing-of-new-oral-cancer-agents
#12
Catherine J Lucas, Jennifer H Martin
Generally, licensed drug-dosing recommendations for chemotherapy are based on results from clinical trials in which subjects are usually of relatively normal body size, middle-aged, and are relatively racially homogeneous, with minimal comorbidity and specific tumor characteristics. Very few nontrial patients meet these characteristics, resulting in clinical practice having to extrapolate dosing recommendations to the specific patient. There is insufficient research on the impact of obesity-associated physiological changes prevalent in patients with common cancers on standard pharmacokinetic and pharmacodynamic parameters...
October 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28912872/preclinical-trial-of-the-multi-targeted-lenvatinib-in-combination-with-cellular-immunotherapy-for-treatment-of-renal-cell-carcinoma
#13
Chengkuan Cai, Jingyuan Tang, Baixin Shen, Liucheng Ding, Yunpeng Shao, Zhengsen Chen, Yinchao Ma, Haoliang Xue, Zhongqing Wei
Lenvatinib is an oral, multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor β, RET and KIT. Cellular immunotherapy has the potential to be a highly targeted treatment, with low toxicity to normal tissues and a high capacity to eradicate tumor tissue. The present study assessed the safety, maximum tolerated dose (MTD) and preliminary antitumor activity of lenvatinib and cellular immunotherapy in a murine model of renal cell carcinoma (RCC)...
October 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28911059/forcing-the-vicious-circle-sarcopenia-increases-toxicity-decreases-response-to-chemotherapy-and-worsens-with-chemotherapy
#14
F Bozzetti
Sarcopenia has recently emerged as a new condition that, independently from malnutrition, may adversely affect the prognosis of cancer patients. Purpose of this narrative review is to define the prevalence of sarcopenia in different primaries, its role in leading to chemotherapy toxicity and decreased compliance with the oncological therapy and the effect of some drugs on the onset of sarcopenia. Finally, the review aims to describe the current approaches to restore the muscle mass through nutrition, exercise and anti-inflammatory agents or multimodal programmes with a special emphasis on the results of randomized controlled trials...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28867970/occurrence-and-recurrence-of-hepatocellular-carcinoma-after-successful-direct-acting-antiviral-therapy-for-patients-with-chronic-hepatitis-c-virus-infection
#15
Sirisha Grandhe, Catherine T Frenette
Chronic hepatitis C virus (HCV) infection has generally been associated with a slightly increased risk of developing hepatocellular carcinoma (HCC). For the past several decades, most patients with chronic HCV cirrhosis have been treated with pegylated interferon and ribavirin therapies, which were known to achieve sustained virologic response (SVR) but also carried their own side effects and toxicities. The recent implementation of direct-acting antiviral (DAA) treatments revealed an increased efficacy in difficult-to-treat populations and higher adherence rates given the all-oral nature of the regimens...
July 2017: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28756607/a-randomized-open-label-two-way-crossover-single-dose-bioequivalence-study-of-temozolomide-200%C3%A2-mg-m-2-dralitem-%C3%A2-vs-temodal-%C3%A2-capsules-in-patients-with-primary-tumors-of-the-central-nervous-system-under-fasting-conditions
#16
Alejandro Muggeri, Miguel Vago, Sebastián Pérez, Marcelo Rubio, Cecilia González, Cristian Magariños, Mónica Rosenberg, Fernando Costa, Santiago Pérez-Lloret
BACKGROUND: Temozolomide is an antineoplastic agent of proven efficacy against high-grade gliomas. PURPOSE: The objective of this crossover, single-dose, bioequivalence study was to compare the rate and extent of absorption of oral temozolomide after administration of the study product (Dralitem(®), Monte Verde Sociedad Anónima) and the reference product (Temodal(®), originator product manufactured by Schering Plough Laboratories) in patients with primary central nervous system (CNS) tumors under fasting conditions...
September 2017: Drugs in R&D
https://www.readbyqxmd.com/read/28698536/metformin-use-associated-with-lower-risk-of-cancer-in-patients-with-diabetes-mellitus-type-2
#17
Jasna Kusturica, Aida Kulo Ćesić, Edis Gušić, Sanita Maleškić, Maida Rakanović-Todić, Damir Šečić
Aim In order to increase the database related to the antineoplastic potential of metformin, association between the use of metformin and risk of cancer occurence in patients with diabetes mellitus type 2 (DM2) was investigated. Methods In this cross-sectional study, medical records of patients with DM2 were reviewed for cancer occurence. Data on age, body mass index (BMI), alcohol and nicotine consumption, glucose and HbA1c levels, duration of DM2, medication used in the treatment of DM2 and cancer occurence were collected and analyzed...
August 1, 2017: Medicinski Glasnik
https://www.readbyqxmd.com/read/28698442/incidence-of-ophthalmic-disorders-in-patients-treated-with-the-antineoplastic-agent-s-1
#18
Kanae Moriya, Hisanori Shimizu, Satoko Handa, Tadanori Sasaki, Yasutsuna Sasaki, Haruo Takahashi, Seigo Nakamura, Hitoshi Yoshida, Yasuhisa Kato
S-1 is an oral antineoplastic agent containing tegafur, gimeracil, and oteracil potassium. Recently, ophthalmic disorders, particularly epiphora, have been reported. We retrospectively investigated the incidence of ophthalmic disorders in patients treated with a regimen containing S-1 at our institution. Ophthalmic disorders were noted in 28 of 261 patients(10.7%). These included epiphora(17 cases), eye discharge(10 cases), conjunctivitis(6cases ), blurred vision(3 cases), and eye discomfort(2 cases), as well as eye pain, pruritus, dry eye, hordeolum, and visual loss(1 case each)...
June 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28667459/clinical-pharmacokinetics-and-pharmacodynamics-of-panobinostat
#19
REVIEW
Mathilde Van Veggel, Elsbeth Westerman, Paul Hamberg
Histone deacetylase (HDAC) inhibitors cause an increase in acetylation that leads to an increase in DNA transcription and accumulation of different proteins, reducing cell proliferation and inducing cell death. Panobinostat is a first-in-line HDAC inhibitor approved for treating multiple myeloma in combination with bortezomib and dexamethasone. It is a pan-deacetylase inhibitor and therefore inhibits not only HDAC but also other deacetylases. The main mechanism of action of panobinostat is to inhibit HDAC, which causes cell cycle arrest and apoptosis, leading to it being an antineoplastic drug...
June 30, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28629835/ruthenium-complex-exerts-antineoplastic-effects-that-are-mediated-by-oxidative-stress-without-inducing-toxicity-in-walker-256-tumor-bearing-rats
#20
Carlos Eduardo Alves de Souza, Helen de Morais Alves de Souza, Maria Carolina Stipp, Claudia Rita Corso, Claudia Martins Galindo, Carolina Riverin Cardoso, Rosangela Locatelli Dittrich, Edneia Amancio de Souza Ramos, Giseli Klassen, Rose Maria Carlos, Sílvia Maria Suter Correia Cadena, Alexandra Acco
The present study evaluated the in vivo antitumor effects and toxicity of a new Ru(II) compound, cis-(Ru[phen]2[ImH]2)(2+) (also called RuphenImH [RuC]), against Walker-256 carcinosarcoma in rats. After subcutaneous inoculation of Walker-256 cells in the right pelvic limb, male Wistar rats received 5 or 10mgkg(-1) RuC orally or intraperitoneally (i.p.) every 3 days for 13 days. A positive control group (2mgkg(-1) cisplatin) and negative control group (vehicle) were also used. Tumor progression was checked daily...
June 17, 2017: Free Radical Biology & Medicine
keyword
keyword
86616
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"